Physician profile
Laura Snyder
NPI 1245897651
$2,353.73
in general payments reported to CMS, 2019-2025
12 companies · $1,414 in 2025
The $1,414 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2021: $72.11 · 2022: $44.91 · 2024: $430 · 2025: $1,414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $988 · Travel and Lodging: $857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $987.67 |
| Travel and Lodging | $857.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $1,089.04 | 2025 | |
| Medwest Associates | $392.00 | 2019 | |
| Depuy Synthes Sales INC. | $354.89 | 2024-2025 | Attune, Healix Knotless Peek, Vapr |
| Vericel Corporation | $149.99 | 2024 | Maci |
| Stryker Corporation | $123.13 | 2022-2025 | Triathlon, Alphavent |
| Lightbody Medical Technologies INC | $83.23 | 2024 | |
| Heron Therapeutics, INC. | $55.91 | 2021 | |
| Surgenex LLC | $33.62 | 2025 | Surmatrix, Ardeograft, Surgraft |
| Vertex Pharmaceuticals Incorporated | $21.96 | 2025 | |
| Janssen Biotech, INC. | $17.19 | 2025 | Tremfya |
| Zimmer Biomet Holdings, INC. | $16.57 | 2025 | Juggerstitch, Juggerknotless Soft Anchor |
| Pacira Pharmaceuticals Incorporated | $16.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.